Kevin O’Connor, partner in the firm’s Intellectual Property group, was recently quoted in MedCity News’ article, “DeepMind has unlocked protein-based medicine – what does that mean for drug patents?” published August 31, 2021. In the article, Kevin discusses his prediction that DeepMind and other AI companies will only continue to use this sort of platform tool to research, recognize, treat and cure disease.

Click here to read the article.